In the treatment of chronic lymphocytic leukemia (CLL), Bruton’s tyrosine kinase (BTK) inhibitors have opened the door to powerful new therapeutic possibilities. While these targeted therapies have redefined standards of care, their cardiovascular (CV) side effects have introduced a new layer of complexity in managing patients, particularly those with preexisting conditions. The France Foundation (TFF) has partnered with the International Cardio-Oncology Society (IC-OS) to create “BTK Inhibitors in CLL: Striking a Balance Between Effectiveness and Heart Health,” a robust educational initiative designed to maximize therapeutic benefit while minimizing CV harm. 

We built this initiative around real-world clinical questions, such as: 

• “Which BTK inhibitor is best for my patient with atrial fibrillation?” 

• “How do I identify a cardiovascular adverse event early enough to act?” 

• “Can I switch a patient from one BTKi to another safely?” 

• “What does long-term monitoring really look like?” 

Designed by TFF Director of Educational Development Barbara Pimienta-Watts and Dr. Daniel Lenihan, and supported by IC-OS Executive Director Stephen Casselli, Ph.D., this program answers those questions and many more by providing practical risk assessment and monitoring strategies, as well as the necessary insights to differentiate the clinical and cardiovascular safety profiles of current and emerging BTK inhibitors. Collaborating with other specialties is just one step towards enhancing treatment; integrating patient preferences into shared clinical decision-making is vital to creating an effective treatment plan. Whether it’s through case-based discussions, mobile-friendly microlearning, or downloadable risk stratification tools, learners get clarity not only on what to do but how to do it safely, collaboratively, and effectively. 

BTK Inhibitors in CLL acts as a blueprint for transforming patient management. Grounded in evidence and built for multidisciplinary impact, it provides a clear path ahead to navigate increasingly complex treatment decisions. Our goal for this initiative is to create an adaptable framework for new therapies amid ever-changing clinical realities. We’re proud to work side by side with IC-OS to accomplish exactly that.  

Curious about how you can collaborate with us on similar initiatives? Help us shape future medical education programs by contacting us through the form below.